EKSO Ekso Bionics Holdings Inc

Ekso raised $22.8m from a warrant exercise in late November and as a result the balance sheet is strengthened and earnings volatility from warrant accounting reduced. Q3 results showed strong unit sales growth, but at a lower average selling price due to a higher proportion of sales made through distributors. We see higher distributor sales as a positive since this will be a key route for sales growth in the mid to long term. Also, in late December, Ekso filed a 510(k) with the FDA as a result of the reclassification of exoskeletons as Class II devices. We have updated our forecasts to take into account Q3 results and a new valuation approach.


Ekso Bionics is a pioneer in the field of human robotic exoskeletons that augment mobility, strength and endurance. It is a development-stage company based in Richmond, California.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports